Fenaux P, Steensma DP, Van Eygen K, et al. Treatment with imetelstat provides durable transfusion independence (TI) in heavily transfused non-del(5q) lower risk MDS (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESAs). 24th Congress of EHA, abstract S837.
Isatuximab, carfilzomib en dexamethason bij gerecidiveerd multipel myeloom (IKEMA)
aug 2021 | MM